on Menarini Industrie Farmaceutiche Riunite
Menarini Group Showcases Phase 2 Elacestrant Data at 2025 SABCS
Menarini Industrie Farmaceutiche Riunite unveiled promising Phase 2 data for elacestrant (ORSERDU®) at the 2025 San Antonio Breast Cancer Symposium. The study, ELEVATE, highlighted the drug's efficacy in combination with everolimus or abemaciclib for patients with ER+, HER2- metastatic breast cancer. Elacestrant demonstrated consistent progression-free survival (PFS) benefits, unaffected by ESR1 mutation status.
Virginia Kaklamani, MD, emphasized elacestrant's potential as a key endocrine therapy in combination treatments. The results showed no new safety concerns, aligning with the known profiles of the combined drugs. This data supports elacestrant's growing role across various treatment regimens, potentially enhancing patient outcomes.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Menarini Industrie Farmaceutiche Riunite news